Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03004625 | Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV | PHASE3 | COMPLETED | 70 | — | — | Nov 1, 2016 | Apr 1, 2018 | Jan 9, 2019 | 1 | Taiwan |
SVR12 is defined as undetectable HCV RNA 12 weeks throughout 12 weeks of post-treatment follow-up peroid
| Arm | Type | Description |
|---|---|---|
| Study Arm | EXPERIMENTAL | HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin) |
| Name | Type | Description |
|---|---|---|
| daclatasvir | DRUG | to evaluate the treatment efficacy and safety of the drug in HCV patients |
| asunaprevir | DRUG | to evaluate the treatment efficacy and safety of the drug in HCV patients |
| Ribavirin | DRUG | to evaluate the treatment efficacy and safety of the drug in HCV patients |
Inclusion Criteria: 1. Treatment naïve, interferon-experienced, interferon-intolerant or interferon-ineligible, HCV genotype 1b patients with compensated liver disease. 2. Patients with compensated liver cirrhosis will be capped at 40%. Cirrhosis is defined as any one of the following: * Liv...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |